ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb has undertaken a research collaboration with Grail, a computer-based DNA-sequencing firm specializing in cancer detection, aimed at developing blood tests that detect cancer in early stages. BMS will gain access to the company’s clinical trial database as a resource in understanding tumor genomics. BMS, along with Johnson & Johnson, Celgene, and others, has invested $900 million in Grail’s series B fundraising round. Grail expects to raise more than $1 billion to advance cancer blood testing before the latest round closes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter